Sirion Biotech GmbH: Adeno-associated virus now easily available for research and preclinical studies
(firmenpresse) - (DGAP-Media / 04.12.2012 / 10:15)
Munich, Bielefeld, Heidelberg (Germany), SIRION Biotech and PlasmidFactory
agreed to actively promote adeno-associated virus (AAV) vectors for
advanced preclinical research. Dr. Oliver Mueller, University of
Heidelberg, will serve as scientific advisor. AAV vectors have been
identified as most promising gene delivery candidates for curative therapy
of gene defects that need long-term treatment. It is estimated that over
4000 human diseases are caused by single gene defects. Besides acting as
highly versatile gene delivery agents they also serve for functional
genomic studies. To date 44 clinical trials are being conducted with AAV
for diseases like Parkinson, Alzheimer or Stage IV Gastric cancer. The
first AAV vector-based gene therapy for lipoprotein lipase deficiency
(LPLD) has been approved in Europe for Human Use just a few weeks ago.
Generating AAV, especially for use in preclinical and clinical applications
requires a mix of skills: plasmid DNA in reproducible and certified quality
both in research and clinical grades, solid experience in generating AAV
vectors for preclinical use and the ability to generate entire cell models
according to desired specifications. This week's agreement between
PlasmidFactory and SIRION Biotech allows for commercial supplies of highly
innovative AAV vectors for preclinical research and up to clinical phase
III studies. Within just 8 weeks SIRION Biotech is able to supply research
quantities for in vivo studies in small animals. Working with AAV vectors
for many more clinical trials is now made a realistic option for
researchers worldwide.
About SIRION BIOTECH, PlasmidFactory and PD Dr. Oliver Müller
SIRION Biotech was founded in 2006 in Munich and has sites in Tokyo and New
Hampshire. It stands for sophisticated cell modelling and viral vector
platforms. These enable much improved target identification and compound
screening in the drug, the food&cosmetic industries. Its technology has
over the years been validated in more than 250 commercial projects with
more than 70 academic and industrial organizations worldwide. As a result,
primary cell immortalizations are being technically advanced, so is the
recombinant virus vector construction serving for gene therapy applications
and novel vaccines.
PlasmidFactory is a biopharmaceutical company, founded in Bielefeld in
2000. Today the company is formed by a young team of biologists, chemists,
engineers and technicians and is Europe's leading contract manufacturer of
plasmid DNA. The company produces clients' plasmids according to their
requirements (incl. GMP use) in modern laboratories with high quality
standards. PlasmidFactory holds the worldwide exclusive license from DKFZ
for manufacturing, distribution and use of the Helper&Packaging Plasmids
from the pDG and pDP family, respectively1.
Dr. Oliver Mueller leads a team at the Dept. of Internal Medicine III at
the University of Heidelberg whose aim is to develop gene therapies for
hereditary heart diseases. The department's research is addressing chronic
diseases by close interaction of medical and biology basic research.
Contact:
SIRION BIOTECH GmbH
Dr. Christian Thirion
Am Klopferspitz 19
D-82152 Martinsried
Tel.: +49-89-700 961 99-15
eMail: Thirion(at)Sirion-Biotech.com
www.Sirion-Biotech.com
PlasmidFactory GmbH&Co. KG
Dr. Martin Schleef
Meisenstr. 96
D-33607 Bielefeld
Tel.: +49-521-299 7350
eMail: info(at)PlasmidFactory.com
www.PlasmidFactory.com
1References:
[1] Grimm et al. (1998), Novel Tools for Production and Purification of
Recombinant Adenoassociated
Virus Vectors, Human Gene Therapy, Vol. 9, 2745-2760.
[2] Raake PWJ, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel
S, Pleger S, Mier W,
Haberkorn U, Katus HA, Koch WJ, Most P, Muller OJ. AAV6.?ARKct cardiac gene
therapy ameliorates
cardiac function and normalizes the catecholaminergic axis in a clinically
relevant large animal
heart failure model. Europ Heart J. Jan 12. (2012) [Epub ahead of print]
[3] Grimm et al. (2003), Helper Virus-Free, Optically Controllable, and
Two-Plasmid-Based Production
of Adeno-associated Virus Vectors of Serotypes 1 to 6, Molecular Therapy,
Vol. 7, 839-850.
[4] Kronenberg et al. (2005), A Conformational Change in the
Adeno-Associated Virus Type 2 Capsid
Leads to the Exposure of Hidden VP1 N Termini, Journal of Virology, Vol.
79, 5296-5303.
[5] Moullier, P. and Snyder, R.O. (2008), International efforts for
recombinant adenoassociated viral
vector reference standards, Molecular Therapy, Vol. 16, 1185-1188
[6] AAV-DNA helper sequences EP 0 934 423
End of Media Release
---------------------------------------------------------------------
Issuer: Sirion Biotech GmbH
Key word(s): Health
04.12.2012 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
195744 04.12.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.12.2012 - 10:15 Uhr
Sprache: Deutsch
News-ID 209204
Anzahl Zeichen: 3234
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sirion Biotech GmbH: Adeno-associated virus now easily available for research and preclinical studies"
steht unter der journalistisch-redaktionellen Verantwortung von
Sirion Biotech GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
